868565-59-7

Basic information

• Product Name: 2-((2-bromophenyl)amino)-2-oxoacetic acid
• Synonyms: 2-((2-bromophenyl)amino)-2-oxoacetic acid
• CAS NO: 868565-59-7
• Molecular Weight: 244.045
• Mol File: 868565-59-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-((2-bromophenyl)amino)-2-oxoacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((2-bromophenyl)amino)-2-oxoacetic acid(868565-59-7)
• EPA Substance Registry System: 2-((2-bromophenyl)amino)-2-oxoacetic acid(868565-59-7)

Safety Data

• Hazardous Substances Data: 868565-59-7(Hazardous Substances Data)

Upstream product

• 1019997-27-3 methyl N-(2-bromophenyl)oxamate 
• 69066-32-6 ethyl 2-((2-bromophenyl)amino)-2-oxoacetate 
• 615-36-1 2-bromoaniline 

Downstream Products

• 1592-00-3 2-bromophenyl isocyanate 

Relevant articles and documents

Supporting-Electrolyte-Free Anodic Oxidation of Oxamic Acids into Isocyanates: An Expedient Way to Access Ureas, Carbamates, and Thiocarbamates

We report a new electrochemical supporting-electrolyte-free method for synthesizing ureas, carbamates, and thiocarbamates via the oxidation of oxamic acids. This simple, practical, and phosgene-free route includes the generation of an isocyanate intermediate in situ via anodic decarboxylation of an oxamic acid in the presence of an organic base, followed by the one-pot addition of suitable nucleophiles to afford the corresponding ureas, carbamates, and thiocarbamates. This procedure is applicable to different amines, alcohols, and thiols. Furthermore, when single-pass continuous electrochemical flow conditions were used and this reaction was run in a carbon graphite Cgr/Cgr flow cell, urea compounds could be obtained in high yields within a residence time of 6 min, unlocking access to substrates that were inaccessible under batch conditions while being easily scalable.

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.